Design and synthesis of a PSMA inhibitor-doxorubicin conjugate for targeted prostate cancer therapy

Sarva Jayaprakash, Xinning Wang, Warren D. Heston, Alan P. Kozikowski

Research output: Contribution to journalArticle

Abstract

Prostate-specific membrane antigen (PSMA) provides an attractive target for the development of targeted chemotherapeutics for prostate cancer. We have designed and synthesized a bioconjugate 1 that comprises the cytotoxic drug doxorubicin and one of our previously described urea-based PSMA inhibitors. While this bioconjugate retained high binding affinity for PSMA, it inhibited only 30% of C4-2 cell growth at a concentration of 5.0 μM.

Original languageEnglish (US)
Pages (from-to)299-302
Number of pages4
JournalChemMedChem
Volume1
Issue number3
DOIs
StatePublished - Mar 2006
Externally publishedYes

Fingerprint

Doxorubicin
Prostatic Neoplasms
Cell growth
Urea
Therapeutics
Growth
Pharmaceutical Preparations
human glutamate carboxypeptidase II

Keywords

  • Doxorubicin
  • Inhibitors
  • Neurotransmitters
  • Prostate cancer
  • PSMA

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Organic Chemistry
  • Molecular Medicine

Cite this

Design and synthesis of a PSMA inhibitor-doxorubicin conjugate for targeted prostate cancer therapy. / Jayaprakash, Sarva; Wang, Xinning; Heston, Warren D.; Kozikowski, Alan P.

In: ChemMedChem, Vol. 1, No. 3, 03.2006, p. 299-302.

Research output: Contribution to journalArticle

Jayaprakash, Sarva ; Wang, Xinning ; Heston, Warren D. ; Kozikowski, Alan P. / Design and synthesis of a PSMA inhibitor-doxorubicin conjugate for targeted prostate cancer therapy. In: ChemMedChem. 2006 ; Vol. 1, No. 3. pp. 299-302.
@article{f3af87c0c3924397b21e9ddf8d15f838,
title = "Design and synthesis of a PSMA inhibitor-doxorubicin conjugate for targeted prostate cancer therapy",
abstract = "Prostate-specific membrane antigen (PSMA) provides an attractive target for the development of targeted chemotherapeutics for prostate cancer. We have designed and synthesized a bioconjugate 1 that comprises the cytotoxic drug doxorubicin and one of our previously described urea-based PSMA inhibitors. While this bioconjugate retained high binding affinity for PSMA, it inhibited only 30{\%} of C4-2 cell growth at a concentration of 5.0 μM.",
keywords = "Doxorubicin, Inhibitors, Neurotransmitters, Prostate cancer, PSMA",
author = "Sarva Jayaprakash and Xinning Wang and Heston, {Warren D.} and Kozikowski, {Alan P.}",
year = "2006",
month = "3",
doi = "10.1002/cmdc.200500044",
language = "English (US)",
volume = "1",
pages = "299--302",
journal = "ChemMedChem",
issn = "1860-7179",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Design and synthesis of a PSMA inhibitor-doxorubicin conjugate for targeted prostate cancer therapy

AU - Jayaprakash, Sarva

AU - Wang, Xinning

AU - Heston, Warren D.

AU - Kozikowski, Alan P.

PY - 2006/3

Y1 - 2006/3

N2 - Prostate-specific membrane antigen (PSMA) provides an attractive target for the development of targeted chemotherapeutics for prostate cancer. We have designed and synthesized a bioconjugate 1 that comprises the cytotoxic drug doxorubicin and one of our previously described urea-based PSMA inhibitors. While this bioconjugate retained high binding affinity for PSMA, it inhibited only 30% of C4-2 cell growth at a concentration of 5.0 μM.

AB - Prostate-specific membrane antigen (PSMA) provides an attractive target for the development of targeted chemotherapeutics for prostate cancer. We have designed and synthesized a bioconjugate 1 that comprises the cytotoxic drug doxorubicin and one of our previously described urea-based PSMA inhibitors. While this bioconjugate retained high binding affinity for PSMA, it inhibited only 30% of C4-2 cell growth at a concentration of 5.0 μM.

KW - Doxorubicin

KW - Inhibitors

KW - Neurotransmitters

KW - Prostate cancer

KW - PSMA

UR - http://www.scopus.com/inward/record.url?scp=33646490408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646490408&partnerID=8YFLogxK

U2 - 10.1002/cmdc.200500044

DO - 10.1002/cmdc.200500044

M3 - Article

C2 - 16892363

AN - SCOPUS:33646490408

VL - 1

SP - 299

EP - 302

JO - ChemMedChem

JF - ChemMedChem

SN - 1860-7179

IS - 3

ER -